Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

NASDAQ:ITRM

Iterum Therapeutics plc

Last Close

1.13

30/08 20:00

Market Cap

24.34M

Beta: 1.61

Volume Today

236.11K

Avg: 63.45K

PE Ratio

−0.61

PFCF: −0.64

People Not Available